Utama › Mieloma Pelbagai › California › San Francisco
Kajian klinikal Mieloma Pelbagai di San Francisco, CA
15 kajian untuk Mieloma Pelbagai sedang mencari peserta di lokasi dalam dan sekitar San Francisco (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Mengambil pesertaFasa 1
- University of California San Francisco, San Francisco
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Mengambil pesertaFasa 2
- University of California San Francisco, San Francisco
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Mengambil pesertaFasa 2
- University of California San Francisco, San Francisco
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 3
- University of California San Francisco, San Francisco
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Mengambil pesertaFasa 4
- University of California San Francisco, San Francisco
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 1/2
- UCSF, San Francisco
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Mengambil pesertaFasa 2
- Kaiser Permanente - South San Francisco Medical Center, San Francisco
- California Pacific Medical Center Research Institute, San Francisco
- Kaiser Permanente - San Francisco Medical Center, San Francisco
- dan 1 lagi
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Mengambil pesertaFasa 1
- University of California, San Francisco, San Francisco
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 2
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- UCSF, San Francisco
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Mengambil pesertaFasa 1/2
- Research Site, San Francisco
Delayed Toxicities Post-CAR-T
Mengambil pesertaKajian pemerhatian
- UCSF Medical Center, San Francisco
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- University of Calfornia, San Francisco, San Francisco
Kajian Mieloma Pelbagai di bandar lain
- New York City, NY60 kajian
- Boston, MA42 kajian
- Atlanta, GA41 kajian
- Houston, TX38 kajian
- Durham, NC37 kajian
- Nashville, TN32 kajian
- Denver, CO27 kajian
- Rochester, MN24 kajian
- St. Louis, MO24 kajian
- Columbus, OH24 kajian
- Baldwin Park, CA23 kajian
- Chicago, IL22 kajian
Kajian lain di San Francisco
- Kanser Prostat45 kajian
- Kanser Payudara43 kajian
- Kanser Paru-paru Bukan Sel Kecil36 kajian
- Kanser (semua jenis)35 kajian
- Kegagalan Jantung29 kajian
- Kanser Metastatik28 kajian
- Kanser Paru-paru23 kajian
- Melanoma22 kajian
- Kanser Pankreas20 kajian
- Kanser Ovari19 kajian
- Kanser Kolorektal18 kajian
- Penyakit Kardiovaskular18 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.